Picture1.jpg
Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic
22 févr. 2024 06h19 HE | Curium
PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...
Picture1.jpg
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
06 févr. 2024 05h23 HE | Curium
Exciting news from Curium! Starting April 5, 2024, our Ioflupane I 123 Injection will be delivered Monday through Friday.
Picture1.jpg
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
23 nov. 2023 07h47 HE | Curium
Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
Curium Announces Fir
Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
16 nov. 2023 05h14 HE | Curium
PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that in partnership with its exclusive distributor SYN Innovation Laboratories in Greece, the...
Η CURIUM ΑΝΑΚΟΙΝΏΝΕΙ
Η CURIUM ΑΝΑΚΟΙΝΏΝΕΙ ΌΤΙ ΟΙ ΠΡΏΤΟΙ ΑΣΘΕΝΕΊΣ ΣΤΗΝ ΕΛΛΆΔΑ ΈΛΑΒΑΝ ΈΝΕΣΗ ΜΕ PYLCLARI® - ΈΝΑΝ ΚΑΙΝΟΤΌΜΟ ΙΧΝΗΘΈΤΗ PET 18F-PSMA ΠΟΥ ΕΝΔΕΊΚΝΥΤΑΙ ΣΕ ΑΣΘΕΝΕΊΣ ΜΕ ΚΑΡΚΊΝΟ ΤΟΥ ΠΡΟΣΤΆΤΗ
16 nov. 2023 05h14 HE | Curium US LLC
ΠΑΡΙΣΙ, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Η Curium, παγκόσμιος ηγέτης στην πυρηνική ιατρική, ανακοίνωσε σήμερα ότι σε συνεργασία με τον αποκλειστικό διανομέα της SYN Innovation Laboratories στην...
Curium and PIUR IMAG
Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to Enable Tomographic 3D Ultrasound Solutions
25 oct. 2023 07h33 HE | Curium
BERLIN, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, and PIUR IMAGING, a European medical device company at the forefront of pioneering tomographic 3D ultrasound...
CURIUM UND PIUR IMAG
CURIUM UND PIUR IMAGING KÜNDIGEN EINE PARTNERSCHAFT FÜR DIE SCHILDDRÜSENBILDGEBUNG IN DEUTSCHLAND AN, UM TOMOGRAPHISCHE 3D-ULTRASCHALLÖSUNGEN ZU ERMÖGLICHEN
25 oct. 2023 07h33 HE | Curium
BERLIN, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen in der Nuklearmedizin, und PIUR IMAGING, ein europäisches Medizintechnikunternehmen, das bei der Entwicklung von...
Picture1.jpg
Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer
07 sept. 2023 04h25 HE | Curium
PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
Picture1.jpg
Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T
15 août 2023 10h50 HE | Curium
PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
Picture1.jpg
Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
28 juil. 2023 06h12 HE | Curium
PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI™ (INN: Piflufolastat...